AstraZeneca (HAM:ZEG) Valuation Rank


HAM:ZEG AstraZeneca PLC HAM:ZEG
88 GF Score
Price €164.30
GF Value €156.57
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

AstraZeneca Valuation Rank Related Terms

HAM:ZEG
88GF Score
AstraZeneca PLC HAM:ZEG
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (HAM:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued. The current stock price of €164.30 is trading 4.9% above its estimated GF Value™ of €156.57. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for HAM:ZEG:

  • Valuation Rank:
  • GF Value™: €156.57 vs. price of €164.30 (4.9% above fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the HAM:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for HAM:ZEG

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€164.30
Price
€156.57
GF Value